Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Chuikyo Plans Monthly Debates for CEA Reform in FY2026
A Japanese reimbursement policy panel on May 14 agreed on its discussion timeline for the next reform of the cost-effectiveness assessment (CEA) system scheduled for FY2026, with a plan to meet around once a month to deepen debates towards the…
To read the full story
Related Article
- Deeper CEA Price Cuts Mooted for “Cost Increase” Products: FY2026 Reform Debate
October 16, 2025
- Rift Surfaces over What Constitutes “Objective Review” of CEA
September 29, 2025
- Industry Urges “Objective Review First” for CEA Reform; Payers Push for Expansion
August 7, 2025
- Japan Begins FY2026 CEA Reform Talks, Re-Designation after Market Expansion Up for Debate
July 17, 2025
REGULATORY
- Japan Eyes Multi-Year Funding to Secure MCMs: Takaichi
October 14, 2026
- Pharma Continues Reform Push at 2nd Public-Private Subgroup Meeting
October 13, 2026
- AbbVie’s TrenibotE Up for Review on Oct. 26, Aquipta on Agenda Too
October 13, 2026
- Japan Panel to Review Full Approval of Nipro’s Stemirac on October 15
October 13, 2026
- Japan Finalizes Medical Data Sharing Blueprint, Eyes 2027 Bill
October 13, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…